It was demonstrated that the CLR gene signature could differentiate the survival of patients with bladder cancer, liver hepatocellular carcinoma, head and neck squamous cell cancer, sarcoma, stomach carcinoma, and uterine carcinosarcoma. Here, DCLK3 is linked to urinary bladder carcinoma.